as needed for tonicityhydrochloric acid to adjust phor sodium hydroxidepurified water to 100 ml______________________________________ the formulation of this invention may be varied to include 1 other acids and bases to adjust the ph 2 other tonicity imparting agents such as sorbitol glycerin and dextrose 3 other antimicrobial preservatives such as other parahydroxy benzoic acid esters sorbate benzoate propionate chlorbutanol phenylethyl alcohol benzalkonium chloride and mercurials 4 other viscosity imparting agents such as sodium carboxymethylcellulose microcrystalline cellulose polyvinylpyrrolidone polyvinyl alcohol and other gums 5 suitable absorption enhancers 6 stabilizing agents such as antioxidants like bisulfite and ascorbate metal chelating agents such as sodium edetate and drug solubility enhancers such as polyethylene glycols the above formulation can be administered as drops sprays aerosols or by any other intranasal dosage form optionally the delivery system can be a unit dose delivery system the volume of solution or suspension delivered per dose can be anywhere from 5 to 400 u03bcl and preferably between 50 to 150 u03bcl delivery systems for these various dosage forms can be dropper bottles plastic squeeze units atomizers nebulizers or pharmaceutical aerosols in either unit dose or multiple dose packages examples of nasal compositions of the above compounds which were tested in vivo are set forth below parts and percentages are by weight unless otherwise indicated male lewis rats weighing approximately 300 g were used all rats were anesthetized with 50 mg kg pentobarbital nembutal commercially available from abbott i p 3 3 bis 4 pyridylmethyl 1 phenylindolin 2 one 1 39 was administered intravenously orally and nasally to compare oral and nasal bioavailability for i v administration a dose of the dihydrochloride of compound 1 39 herein referred to as compound 1 34 equivalent to.